Experimental cell therapy targets Tough-to-Treat lupus
NCT ID NCT06946485
Summary
This early-stage study is testing a new type of cell therapy called CHT101 for people with severe lupus that hasn't responded to standard treatments. Doctors will collect and modify a patient's own immune cells to target a specific protein involved in lupus, then infuse them back. The main goals are to see if this approach is safe and if it can reduce lupus disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RECRUITINGNanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.